Starling Oncology, Inc.: net_income
| Value | {"amount": -8339904, "concept": "us-gaap:NetIncomeLoss", "currency": "USD"} |
|---|---|
| Period | 2020-01-01 – 2020-12-31 |
| Status | superseded |
| Entity | Starling Oncology, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:08:36.054940+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/8dc98d42-49e3-4d08-8bb4-a67a8cff08a3
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001104659-21-070662Retrieved: 2026-08-19T18:08:36.054940+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001799191/net-income/2020-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/8dc98d42-49e3-4d08-8bb4-a67a8cff08a3
History
- supersedes {"amount": -441154, "concept": "us-gaap:NetIncomeLoss", "currency": "USD"} (evidence 0001104659-21-044010)